CHRS - Coherus Biosciences Inc Stock Price, Fair Value and News

1.72USD+0.14 (+8.86%)Market Closed

Market Summary

USD1.72+0.14

Market Closed

8.86%

CHRS Alerts

Temasek Holdings (Private) Ltd reported owning 4.8% of CHRS [2024-07-23]

CHRS Stock Price

View Fullscreen

CHRS RSI Chart

CHRS Valuation

Market Cap

197.3M

Price/Earnings (Trailing)

-3.33

Price/Sales (Trailing)

0.65

EV/EBITDA

4.67

Price/Free Cashflow

-1.29

CHRS Price/Sales (Trailing)

CHRS Profitability

EBT Margin

-19.77%

Return on Equity

72.44%

Return on Assets

-7.76%

Free Cashflow Yield

-77.49%

CHRS Fundamentals

CHRS Revenue

Revenue (TTM)

301.9M

Rev. Growth (Yr)

137.58%

Rev. Growth (Qtr)

-15.8%

CHRS Earnings

Earnings (TTM)

-59.3M

Earnings Growth (Yr)

235.85%

Earnings Growth (Qtr)

229.15%

Breaking Down CHRS Revenue

Last 30 days

-0.6%

Last 90 days

-23.0%

Trailing 12 Months

-65.3%

How does CHRS drawdown profile look like?

CHRS Financial Health

Current Ratio

1.17

CHRS Investor Care

Shares Dilution (1Y)

42.42%

Diluted EPS (TTM)

-0.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	301.9M	0	0	0
2023	183.4M	181.9M	211.1M	257.2M
2022	303.6M	276.1M	239.1M	211.0M
2021	442.7M	394.6M	363.6M	326.6M
2020	435.1M	487.4M	489.3M	475.8M
2019	284.9M	308.6M	332.3M	356.1M
2017	0	213.8M	237.5M	261.2M
2016	36.6M	43.8M	199.5M	190.1M
2015	33.3M	35.2M	26.3M	30.0M
2014	5.8M	10.3M	25.8M	31.1M
2013	2.1M	2.3M	2.5M	2.8M
2012	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CEO	Mr. Dennis M. Lanfear
WEBSITE	coherus.com
INDUSTRY	Biotechnology
EMPLOYEES	294

Coherus Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Coherus Biosciences Inc? What does CHRS stand for in stocks?

CHRS is the stock ticker symbol of Coherus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Coherus Biosciences Inc (CHRS)?

As of Thu Jul 25 2024, market cap of Coherus Biosciences Inc is 181.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CHRS stock?

You can check CHRS's fair value in chart for subscribers.

Is Coherus Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CHRS is over valued or under valued. Whether Coherus Biosciences Inc is cheap or expensive depends on the assumptions which impact Coherus Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CHRS.

What is Coherus Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, CHRS's PE ratio (Price to Earnings) is -3.06 and Price to Sales (PS) ratio is 0.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CHRS PE ratio will change depending on the future growth rate expectations of investors.